{"id":8021,"date":"2026-01-07T13:23:50","date_gmt":"2026-01-07T21:23:50","guid":{"rendered":"https:\/\/metastatictrialtalk.org\/?p=7837"},"modified":"2026-01-07T13:23:50","modified_gmt":"2026-01-07T21:23:50","slug":"sabcs-2025-2-2","status":"publish","type":"post","link":"https:\/\/breastcancertrialtalk.org\/?p=8021","title":{"rendered":"San Antonio Breast Cancer Symposium 2025"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-6812 size-medium alignleft\" src=\"https:\/\/breastcancertrialtalk.org\/wp-content\/uploads\/Conference-Talk-Lobular-300x200.jpeg\" alt=\"\" width=\"300\" height=\"200\" \/><span style=\"font-size: 12pt; color: #333333;\" data-contrast=\"none\">The 2025 San Antonio Breast Cancer Symposium (SABCS) meeting was held December 9-12, 2025 in San Antonio, TX and virtually. Click the links below to read about MBC research reported at this meeting.<\/span><\/p>\n<h6><span style=\"font-size: 12pt; color: #333333;\"><b>Overview of SABCS 2025<\/b><\/span><\/h6>\n<ul>\n<li><span style=\"font-size: 12pt;\"><span style=\"color: #333333;\">Living Beyond Breast Cancer (video):<\/span> <span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.lbbc.org\/community\/events\/updates-from-2025-san-antonio-breast-cancer-symposium?utm_source=program&amp;utm_medium=email&amp;utm_campaign=sabcs_webinar#video\" target=\"_blank\" rel=\"noopener\">Dr. Harold J. Burstein reviews important studies reported at SABCS 2025<\/a><\/span> <span style=\"color: #333333;\">(studies of HER2+ MBC from 17:02-26:39; studies of HR+, HER- MBC from 37:49-40:00 and 40:57-41:40; studies of triple negative MBC from 40:00-40:57)<\/span><\/span><\/li>\n<li><span style=\"font-size: 12pt;\"><span style=\"color: #333333;\">Living Beyond Breast Cancer:<\/span> <span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.lbbc.org\/news\/whats-next-for-metastatic-breast-cancer-treatments-sabcs-2025\" target=\"_blank\" rel=\"noopener\">This article reviews data presented at SABCS 2025 about drug treatments for the different subtypes of MBC<\/a><\/span><\/span><\/li>\n<\/ul>\n<h6><span style=\"font-size: 12pt; color: #333333;\"><b>Brain and Leptomeningeal Metastases<\/b><\/span><\/h6>\n<ul>\n<li><span style=\"font-size: 12pt;\"><span style=\"color: #333333;\">Reveal Genomics:<\/span> <span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.reveal-genomics.com\/press-releases\/sabcs-2025-reveal-genomics-presents-major-advance-in-predicting-brain-metastasis-in-her2-breast-cancer#:~:text=SABCS%202025:%20REVEAL%20GENOMICS%20PRESENTS%20MAJOR%20ADVANCE,RNA%2Dbased%20ERBB2%20assessment%20to%20accelerate%20clinical%20decision%2Dmaking.\" target=\"_blank\" rel=\"noopener\">A new genomic test predicts overall survival and the risk of brain metastases in people with advanced HER2-positive breast cancer<\/a><\/span><\/span><\/li>\n<li><span style=\"font-size: 12pt;\"><span style=\"color: #333333;\">Breastcancer.org:<\/span> <span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.breastcancer.org\/news\/sabcs-2025-highlights\" target=\"_blank\" rel=\"noopener\">A small study suggests that datopotamab deruxtecan (Dato-DXd; Datroway\u00ae) may help people with breast cancer that has spread to the leptomeninges live longer without their cancer growing if they had not previously received an antibody-drug conjugate<\/a> <\/span><span style=\"color: #333333;\">(scroll to \u201cDato-DXd may help treat leptomeningeal disease\u201d)<\/span><\/span><\/li>\n<\/ul>\n<h6><span style=\"font-size: 12pt; color: #333333;\"><b>HER2+ MBC<\/b><\/span><\/h6>\n<ul>\n<li><span style=\"font-size: 12pt;\"><span style=\"color: #333333;\">Breastcancer.org:<\/span><span style=\"color: #339966;\"> <a style=\"color: #339966;\" href=\"https:\/\/www.breastcancer.org\/news\/sabcs-2025-highlights\" target=\"_blank\" rel=\"noopener\">Results from the HER2CLIMB-05 clinical trial show that adding tucatinib (Tukysa\u00ae) to standard treatments (trastuzumab (Herceptin\u00ae) and pertuzumab (Perjeta\u00ae)) increases progression-free survival by about 9 months<\/a><\/span> <span style=\"color: #333333;\">(scroll to \u201cAdding Tukysa\u2026)<\/span><\/span><\/li>\n<\/ul>\n<h6><span style=\"font-size: 12pt; color: #333333;\"><b>ER+, HER2- MBC<\/b><\/span><\/h6>\n<ul>\n<li><span style=\"font-size: 12pt;\"><span style=\"color: #333333;\">Cancer Network:<\/span> <span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.cancernetwork.com\/view\/pfs-continues-to-improve-with-imlunestrant-in-advanced-breast-cancer\" target=\"_blank\" rel=\"noopener\">The phase III EMBER-3 trial showed that progression-free survival with imlunestrant (Inluriyo\u00ae) plus abemaciclib (Verzenio\u00ae) was 10.9 months compared to 5.5 months for imlunestrant alone in people with previously treated ER+, HER2- advanced breast cancer<\/a><\/span><\/span><\/li>\n<\/ul>\n<h6><span style=\"font-size: 12pt; color: #333333;\"><b>Triple Negative MBC<\/b><\/span><\/h6>\n<ul>\n<li><span style=\"font-size: 12pt;\"><span style=\"color: #333333;\">MedPage Today:<\/span> <span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.medpagetoday.com\/meetingcoverage\/sabcs\/119040?xid=nl_mpt_DHE_2025-12-16&amp;mh=a5b163f9bc8ee8a077e31262b4e7fbea&amp;zdee=gAAAAABm4uO7C7ZaFGb-lPkv0XjdXPudJVqo8AKQVbmnDdExKpj1FRqIByijunUeZWaP0WGnNfVuYc5IhvmduVfuvx40EIVkpXfRiiie6AGLsf0JbXchHPY%3D&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=Daily%20Headlines%20Evening%20-%20Randomized%202025-12-16&amp;utm_term=NL_Daily_DHE_dual-gmail-definition\" target=\"_blank\" rel=\"noopener\">More than two-thirds of people with triple negative MBC responded to the bispecific antibody pumitamig plus chemotherapy<\/a><\/span><\/span><\/li>\n<\/ul>\n<h6><span style=\"font-size: 12pt; color: #333333;\"><b>Support for Black Women<\/b><\/span><\/h6>\n<ul>\n<li><span style=\"font-size: 12pt;\"><span style=\"color: #333333;\">Fierce Pharma:<\/span> <span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.fiercepharma.com\/marketing\/az-gilead-backed-program-reduced-side-effects-distress-black-breast-cancer-patients-study\" target=\"_blank\" rel=\"noopener\">TOUCH, the Black Breast Cancer Alliance and Unite for HER reported that their program for Black women with breast cancer called Care for HER helped reduce distress, side effects, and financial concerns<\/a><\/span><\/span><\/li>\n<li><span style=\"font-size: 12pt;\"><span style=\"color: #333333;\">LinkedIn:<\/span> <span style=\"color: #339966;\"><a style=\"color: #339966;\" href=\"https:\/\/www.linkedin.com\/posts\/ricki-fairley-561a43_a-new-study-reveals-that-integrative-therapy-activity-7405265003303313408-WeEQ\/?utm_source=share&amp;utm_medium=member_desktop&amp;rcm=ACoAAACU6BYBikuVQDWklmwBhCi9cowRJFCyzc8\" target=\"_blank\" rel=\"noopener\">You can view the poster here<\/a><\/span><span style=\"color: #333333;\"> (A LinkedIn account may be required to view this link)<\/span><\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>The San Antonio Breast Cancer Symposium (SABCS) recently held its 2025 conference from December 9-12, 2025. Click to read MBC-related reports from this meeting.<\/p>\n","protected":false},"author":1,"featured_media":7584,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_genesis_block_theme_hide_title":false,"footnotes":""},"categories":[11],"tags":[32,64],"class_list":{"0":"post-8021","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","6":"hentry","7":"category-conference-talk","8":"tag-conference-talk","9":"tag-other-mbc-conferences","11":"with-featured-image"},"featured_image_src":"https:\/\/breastcancertrialtalk.org\/wp-content\/uploads\/2025\/03\/AdobeStock_148440999-1-2-1.png","featured_image_src_square":"https:\/\/breastcancertrialtalk.org\/wp-content\/uploads\/2025\/03\/AdobeStock_148440999-1-2-1.png","author_info":{"display_name":"bctt","author_link":"https:\/\/breastcancertrialtalk.org\/?author=1"},"_links":{"self":[{"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=\/wp\/v2\/posts\/8021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8021"}],"version-history":[{"count":0,"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=\/wp\/v2\/posts\/8021\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=\/wp\/v2\/media\/7584"}],"wp:attachment":[{"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/breastcancertrialtalk.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}